Evolus Appoints Ashwin K. Agarwal as Vice President, Finance, Investor Relations and Treasury
IRVINE, Calif., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today announced the appointment of Ashwin K. Agarwal as Vice President, Finance, Investor Relations, and Treasury, effective immediately. Mr. Agarwal joins Evolus from Alder BioPharmaceuticals where he served as Vice President, Corporate Strategy and brings with him over 20 years of both operational and corporate finance, investor relations, and accounting experience, from his time at both early and late stage healthcare companies.
Earlier in his career, Mr. Agarwal served as Vice President, Finance and Investor Relations at a medical aesthetics start-up and also held roles of increasing responsibility at Allergan for fifteen years, most recently as Senior Director of Finance and Investor Relations. Mr. Agarwal began his career at KPMG where he spent 3 years in the auditing practice. He holds an MBA with an emphasis in Corporate Finance from the University of Southern California Marshall School of Business and a BA in Accounting from California State University, Fullerton.
Lauren Silvernail, Chief Financial Officer and EVP, Corporate Development of Evolus, commented, “Ashwin has deep experience across a range of leadership roles in investor relations, financing growth businesses, supporting business development transactions and building successful long-term plans with senior leadership. We are pleased to welcome him to our team as we drive towards commercialization of DWP-450 in Spring 2019.”
About Evolus, Inc.
Evolus is a company dedicated to aesthetic medicine focused on providing physicians and their patients with expanded choices in aesthetic treatments and procedures. Evolus’ lead candidate DWP-450, also known by the chemical name prabotulinumtoxinA, is a 900 kDa purified botulinum toxin type A complex that was approved by Health Canada for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients under 65 years of age and is being evaluated for marketing approval in the United States and other areas.
Forward-Looking Statements
Statements made in this press release that relate to future plans, events, prospects or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words “planned,” “expect,” “believes,” “strategy,” “opportunity,” “anticipates,” “outlook,” “designed,” and similar words. While these forward-looking statements are based on the current expectations and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in Evolus’ periodic filings with the Securities and Exchange Commission, including factors described in the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2017; its Quarterly Report on Form 10-Q for the Quarter ended June 30, 2018, as filed with the Securities and Exchange Commission on March 29, 2018, May 10, 2018 and August 2, 2018, respectively, all of which are available online at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Evolus undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.
Evolus Contacts:
Investor Contact:
Ashwin Agarwal, Evolus
Tel:
Email:
Brian Johnston, The Ruth Group
Tel:
Email:
Media:
Kirsten Thomas, The Ruth Group
Tel:
Email:
